Gelnique
Gelnique
RESIZE TEXT   |  A  |  A  
 

Information for pharmacists

Important information about Gelnique®—the first and only gel for overactive bladder

Dear Pharmacist:

Healthcare providers have the option of prescribing a unique gel formulation—Gelnique (oxybutynin chloride) Gel 10%—to treat patients with overactive bladder (OAB). Gelnique is being marketed by Watson Pharma, Inc.

Gelnique delivers oxybutynin in an easy-to-use, once-daily topical gel that patients rub onto their skin for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency.1

Efficacy highlights

  • Gelnique has been shown to significantly reduce the number of incontinence episodes per day1,*,‡
  • Patients experienced a 71% reduction in incontinence episodes2,*,§

How Gelnique is applied

  • Patients can apply Gelnique after showering in the morning or at night, as long as the time is consistent from day to day
  • Patients should be advised to rotate application sites, which include the upper arms/shoulders, thighs, or abdomen, daily1

How Gelnique is supplied

  • Gelnique is available as a 1-month supply of thirty (30) 1-gram unit dose (1.14 mL) sachets contained in a box1
  • Each sachet contains 100 mg/g oxybutynin chloride gel1

Favorable safety profile1,*

Gelnique has a low incidence of bothersome side effects that can make patients stop treatment—such as dry mouth and constipation.1 Gelnique is absorbed directly into the bloodstream through the skin and bypasses the gastric system and first-pass metabolism of the liver.1 Avoiding first-pass metabolism reduces the amount of N-desethyloxybutynin (N-DEO) metabolite in the bloodstream.1 Researchers believe that N-DEO may play a role in the development of drying side effects with oral oxybutynin, such as dry mouth.4,5

  • Anticholinergic adverse events—such as dry mouth, constipation, and dizziness—were only 6.9%, 1.3%, and 1.5%, respectively, in a clinical trial1,†
  • No serious adverse events related to treatment were reported1

The most commonly reported adverse events associated with the use of Gelnique included dry mouth (6.9%), urinary tract infection (6.9%), and application site reactions (5.4%). Most treatment-related adverse events were described as mild or moderate in intensity. Only 0.8% of Gelnique-treated patients discontinued treatment in a clinical trial due to application site reactions, compared with 0.3% for placebo.1

If you have any questions, please call 1-888-GELNIQUE (1-888-435-6478). On behalf of Watson Pharma, Inc., thank you for your continued support.

 

*In a phase 3, 12-week, randomized, double-blind, placebo-controlled, parallel group study comparing Gelnique (n=389) to placebo (n=400).

Incidence with placebo: dry mouth, 2.8%; constipation, 1.0%; dizziness, 0.5%.3

Mean change from baseline: Gelnique, -3.0; placebo, -2.5 (P<0.0001).1

§Represents median change from baseline. Reduction with placebo was 55.6%.2